Table 2: Open in new tab Genomic...

Enriched Gene	Enrichment Trend	Liver Frequency		Lung Frequency
TP53	Mutations	82.0%	>	71.3%
MYC	Amplifications	8.9%	>	2.8%
CDK2NA	Mutations/Loss	52.1%	>	38.0%
SMAD4	Mutations/Loss	24.4%	>	16.2%
SWI/SNF	Mutations/Loss	11.8%	>	4.9%
STK11	Mutations	2.5%	<	7.0%
CCND1	Amplifications	0.58%	<	2.82%
GNAS	Alterations	2.0%	<	7.8%
KRAS [ANY]	Mutations	91.9	~	90.9
KRAS G12D	G12D Variant	40.6	~	33.8
KRAS G12V	G12V Variant	27.6	~	31.0
KRAS G12R	G12R Variant	15.2	~	15.5
KRAS Q61	Q61 Variant	4.8	~	7.8
KRAS G12C	G12C Variant	2.0	~	0.0
KRAS ETC	Other Alterations	1.6	~	2.8
ARID1A	Mutations/Loss	7.1	~	3.5
MTAP	Mutations/Loss	6.0	~	4.2
GATA6	Mutations/Loss	5.1	~	5.6
BRCA2	Mutations/Loss	5.1	~	4.9
AKT2	Mutations/Amplifications	3.5	~	4.2
ATM	Mutations/Loss	3.6	~	2.8
KDM6A	Mutations/Loss	3.8	~	1.4
RNF43	Mutations/Loss	3.3	~	3.5
CCNE1	Amplifications	3.3	~	1.4
KMT2D	Mutations/Loss	2.9	~	3.5
CDK6	Amplifications	2.6	~	3.5
SMARCA	Mutations/Loss	2.9	~	0.7
PIK3CA	Mutations/Amplifications	2.8	~	1.4
DNMT3A	Mutations/Loss	2.8	~	0.7
MAP2K4	Mutations/Amplifications	2.8	~	0.0
ERBB2	Mutations/Amplifications	2.3	~	2.1
KDM5A	Mutations/Loss	2.0	~	1.4
LRP1B	Mutations/Loss	2.0	~	1.4
RB1	Mutations/Loss	2.0	~	1.4
SF3B1	Mutations/Loss	2.0	~	1.4
BRCA1	Mutations/Loss	1.7	~	2.1
U2AF1	Mutations/Loss	1.9	~	1.4
ZNF703	Mutations/Loss	2.0	~	0.0
KMT2C	Mutations/Loss	1.5	~	2.8
FGFR1	Mutations/Amplifications	1.9	~	0.0
CCND2	Amplifications	1.7	~	0.7
CHEK2	Mutations/Loss	1.7	~	0.7

Enriched Gene

Enrichment Trend

Liver Frequency

Lung Frequency

TP53

Mutations

82.0%

71.3%

MYC

Amplifications

8.9%

2.8%

CDK2NA

Mutations/Loss

52.1%

38.0%

SMAD4

Mutations/Loss

24.4%

16.2%

SWI/SNF

Mutations/Loss

11.8%

4.9%

STK11

Mutations

2.5%

7.0%

CCND1

Amplifications

0.58%

2.82%

GNAS

Alterations

2.0%

7.8%

KRAS [ANY]

Mutations

91.9

90.9

KRAS G12D

G12D Variant

40.6

33.8

KRAS G12V

G12V Variant

27.6

31.0

KRAS G12R

G12R Variant

15.2

15.5

KRAS Q61

Q61 Variant

4.8

7.8

KRAS G12C

G12C Variant

2.0

0.0

KRAS ETC

Other Alterations

1.6

2.8

ARID1A

Mutations/Loss

7.1

3.5

MTAP

Mutations/Loss

6.0

4.2

GATA6

Mutations/Loss

5.1

5.6

BRCA2

Mutations/Loss

5.1

4.9

AKT2

Mutations/Amplifications

3.5

4.2

ATM

Mutations/Loss

3.6

2.8

KDM6A

Mutations/Loss

3.8

1.4

RNF43

Mutations/Loss

3.3

3.5

CCNE1

Amplifications

3.3

1.4

KMT2D

Mutations/Loss

2.9

3.5

CDK6

Amplifications

2.6

3.5

SMARCA

Mutations/Loss

2.9

0.7

PIK3CA

Mutations/Amplifications

2.8

1.4

DNMT3A

Mutations/Loss

2.8

0.7

MAP2K4

Mutations/Amplifications

2.8

0.0

ERBB2

Mutations/Amplifications

2.3

2.1

KDM5A

Mutations/Loss

2.0

1.4

LRP1B

Mutations/Loss

2.0

1.4

RB1

Mutations/Loss

2.0

1.4

SF3B1

Mutations/Loss

2.0

1.4

BRCA1

Mutations/Loss

1.7

2.1

U2AF1

Mutations/Loss

1.9

1.4

ZNF703

Mutations/Loss

2.0

0.0

KMT2C

Mutations/Loss

1.5

2.8

FGFR1

Mutations/Amplifications

1.9

0.0

CCND2

Amplifications

1.7

0.7

CHEK2

Mutations/Loss

1.7

0.7

Enriched Gene	Enrichment Trend	Liver Frequency		Lung Frequency
TP53	Mutations	82.0%	>	71.3%
MYC	Amplifications	8.9%	>	2.8%
CDK2NA	Mutations/Loss	52.1%	>	38.0%
SMAD4	Mutations/Loss	24.4%	>	16.2%
SWI/SNF	Mutations/Loss	11.8%	>	4.9%
STK11	Mutations	2.5%	<	7.0%
CCND1	Amplifications	0.58%	<	2.82%
GNAS	Alterations	2.0%	<	7.8%
KRAS [ANY]	Mutations	91.9	~	90.9
KRAS G12D	G12D Variant	40.6	~	33.8
KRAS G12V	G12V Variant	27.6	~	31.0
KRAS G12R	G12R Variant	15.2	~	15.5
KRAS Q61	Q61 Variant	4.8	~	7.8
KRAS G12C	G12C Variant	2.0	~	0.0
KRAS ETC	Other Alterations	1.6	~	2.8
ARID1A	Mutations/Loss	7.1	~	3.5
MTAP	Mutations/Loss	6.0	~	4.2
GATA6	Mutations/Loss	5.1	~	5.6
BRCA2	Mutations/Loss	5.1	~	4.9
AKT2	Mutations/Amplifications	3.5	~	4.2
ATM	Mutations/Loss	3.6	~	2.8
KDM6A	Mutations/Loss	3.8	~	1.4
RNF43	Mutations/Loss	3.3	~	3.5
CCNE1	Amplifications	3.3	~	1.4
KMT2D	Mutations/Loss	2.9	~	3.5
CDK6	Amplifications	2.6	~	3.5
SMARCA	Mutations/Loss	2.9	~	0.7
PIK3CA	Mutations/Amplifications	2.8	~	1.4
DNMT3A	Mutations/Loss	2.8	~	0.7
MAP2K4	Mutations/Amplifications	2.8	~	0.0
ERBB2	Mutations/Amplifications	2.3	~	2.1
KDM5A	Mutations/Loss	2.0	~	1.4
LRP1B	Mutations/Loss	2.0	~	1.4
RB1	Mutations/Loss	2.0	~	1.4
SF3B1	Mutations/Loss	2.0	~	1.4
BRCA1	Mutations/Loss	1.7	~	2.1
U2AF1	Mutations/Loss	1.9	~	1.4
ZNF703	Mutations/Loss	2.0	~	0.0
KMT2C	Mutations/Loss	1.5	~	2.8
FGFR1	Mutations/Amplifications	1.9	~	0.0
CCND2	Amplifications	1.7	~	0.7
CHEK2	Mutations/Loss	1.7	~	0.7

Table 2:

Open in new tab

Genomic alteration frequencies in lung- vs. liver-metastasizing PDAC.

Enriched Gene	Enrichment Trend	Liver Frequency		Lung Frequency
TP53	Mutations	82.0%	>	71.3%
MYC	Amplifications	8.9%	>	2.8%
CDK2NA	Mutations/Loss	52.1%	>	38.0%
SMAD4	Mutations/Loss	24.4%	>	16.2%
SWI/SNF	Mutations/Loss	11.8%	>	4.9%
STK11	Mutations	2.5%	<	7.0%
CCND1	Amplifications	0.58%	<	2.82%
GNAS	Alterations	2.0%	<	7.8%
KRAS [ANY]	Mutations	91.9	~	90.9
KRAS G12D	G12D Variant	40.6	~	33.8
KRAS G12V	G12V Variant	27.6	~	31.0
KRAS G12R	G12R Variant	15.2	~	15.5
KRAS Q61	Q61 Variant	4.8	~	7.8
KRAS G12C	G12C Variant	2.0	~	0.0
KRAS ETC	Other Alterations	1.6	~	2.8
ARID1A	Mutations/Loss	7.1	~	3.5
MTAP	Mutations/Loss	6.0	~	4.2
GATA6	Mutations/Loss	5.1	~	5.6
BRCA2	Mutations/Loss	5.1	~	4.9
AKT2	Mutations/Amplifications	3.5	~	4.2
ATM	Mutations/Loss	3.6	~	2.8
KDM6A	Mutations/Loss	3.8	~	1.4
RNF43	Mutations/Loss	3.3	~	3.5
CCNE1	Amplifications	3.3	~	1.4
KMT2D	Mutations/Loss	2.9	~	3.5
CDK6	Amplifications	2.6	~	3.5
SMARCA	Mutations/Loss	2.9	~	0.7
PIK3CA	Mutations/Amplifications	2.8	~	1.4
DNMT3A	Mutations/Loss	2.8	~	0.7
MAP2K4	Mutations/Amplifications	2.8	~	0.0
ERBB2	Mutations/Amplifications	2.3	~	2.1
KDM5A	Mutations/Loss	2.0	~	1.4
LRP1B	Mutations/Loss	2.0	~	1.4
RB1	Mutations/Loss	2.0	~	1.4
SF3B1	Mutations/Loss	2.0	~	1.4
BRCA1	Mutations/Loss	1.7	~	2.1
U2AF1	Mutations/Loss	1.9	~	1.4
ZNF703	Mutations/Loss	2.0	~	0.0
KMT2C	Mutations/Loss	1.5	~	2.8
FGFR1	Mutations/Amplifications	1.9	~	0.0
CCND2	Amplifications	1.7	~	0.7
CHEK2	Mutations/Loss	1.7	~	0.7

Enriched Gene	Enrichment Trend	Liver Frequency		Lung Frequency
TP53	Mutations	82.0%	>	71.3%
MYC	Amplifications	8.9%	>	2.8%
CDK2NA	Mutations/Loss	52.1%	>	38.0%
SMAD4	Mutations/Loss	24.4%	>	16.2%
SWI/SNF	Mutations/Loss	11.8%	>	4.9%
STK11	Mutations	2.5%	<	7.0%
CCND1	Amplifications	0.58%	<	2.82%
GNAS	Alterations	2.0%	<	7.8%
KRAS [ANY]	Mutations	91.9	~	90.9
KRAS G12D	G12D Variant	40.6	~	33.8
KRAS G12V	G12V Variant	27.6	~	31.0
KRAS G12R	G12R Variant	15.2	~	15.5
KRAS Q61	Q61 Variant	4.8	~	7.8
KRAS G12C	G12C Variant	2.0	~	0.0
KRAS ETC	Other Alterations	1.6	~	2.8
ARID1A	Mutations/Loss	7.1	~	3.5
MTAP	Mutations/Loss	6.0	~	4.2
GATA6	Mutations/Loss	5.1	~	5.6
BRCA2	Mutations/Loss	5.1	~	4.9
AKT2	Mutations/Amplifications	3.5	~	4.2
ATM	Mutations/Loss	3.6	~	2.8
KDM6A	Mutations/Loss	3.8	~	1.4
RNF43	Mutations/Loss	3.3	~	3.5
CCNE1	Amplifications	3.3	~	1.4
KMT2D	Mutations/Loss	2.9	~	3.5
CDK6	Amplifications	2.6	~	3.5
SMARCA	Mutations/Loss	2.9	~	0.7
PIK3CA	Mutations/Amplifications	2.8	~	1.4
DNMT3A	Mutations/Loss	2.8	~	0.7
MAP2K4	Mutations/Amplifications	2.8	~	0.0
ERBB2	Mutations/Amplifications	2.3	~	2.1
KDM5A	Mutations/Loss	2.0	~	1.4
LRP1B	Mutations/Loss	2.0	~	1.4
RB1	Mutations/Loss	2.0	~	1.4
SF3B1	Mutations/Loss	2.0	~	1.4
BRCA1	Mutations/Loss	1.7	~	2.1
U2AF1	Mutations/Loss	1.9	~	1.4
ZNF703	Mutations/Loss	2.0	~	0.0
KMT2C	Mutations/Loss	1.5	~	2.8
FGFR1	Mutations/Amplifications	1.9	~	0.0
CCND2	Amplifications	1.7	~	0.7
CHEK2	Mutations/Loss	1.7	~	0.7

This Feature Is Available To Subscribers Only